

ANNEX 2

Country profiles

Countries

This annex presents TB profiles for the 22 high burden countries that account for approximately 80% of all new TB cases arising each year.

TB profiles for all countries and NTP financing profiles for over 100 countries are available at www.who.int/tb/data.

Data source

Data shown in this annex are taken from the WHO global TB database on 2 September 2011. Data shown in the main part of the report were taken from the database on 21 June 2011.

Notification data were updated by Bangladesh, the Russian Federation and South Africa between 21 June and 2 September 2011. As a result, their notification data in this annex differ slightly from those presented in the main part of the report.

AFGHANISTAN

POPULATION 2010 (MILLIONS) **31**

ESTIMATES OF BURDEN 2010 ^a	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	12 (8.6–16)	38 (27–50)
Prevalence (incl HIV)	110 (51–180)	352 (162–578)
Incidence (incl HIV)	59 (49–71)	189 (155–226)
Incidence (HIV-positive)		
Case detection, all forms (%)	47 (39–57)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	12 947 (48)	Relapse	1 116 (84)
Smear-negative	4 479 (17)	Treatment after failure	147 (11)
Smear unknown	2 606 (10)	Treatment after default	62 (5)
Extrapulmonary	6 248 (23)	Other	
Other	633 (2)		
Total new	26 913	Total retreatment	1 325
Total < 15 years	642		

Total new and relapse	28 029	(99% of total)
Total cases notified	28 238	


DRUG REGIMENS

Rifampicin used throughout treatment	No
% of patients treated with fixed-dose combinations (FDCs)	100
Paediatric formulations procured	Yes

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	86
New smear-negative/extrapulmonary	
Retreatment	

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	6.1 (3.5–10)
% of retreatment TB cases with MDR-TB	8.3 (1.7–21)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	1 300 (720–2 100)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	110 (23–280)

MDR-TB REPORTED CASES 2010	New	Retreatment	Total
Cases tested for MDR-TB	238	34	272
% of notified tested for MDR-TB	<1	3	<1
Confirmed cases of MDR-TB	13	6	19
MDR-TB patients started treatment			0


LABORATORIES	2009	2010	2011
Smear (per 100 000 population)	1.9	1.9	1.9
Culture (per 5 million population)	0	0.2	0.6
DST (per 5 million population)	0	0	0

Second-line DST available	Outside country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	5 170
% of TB patients with known HIV status	18
TB patients that are HIV-positive	0
% of tested TB patients that are HIV-positive	0
% HIV-positive TB patients started on CPT	
% HIV-positive TB patients started on ART	
HIV-positive people screened for TB	
HIV-positive people provided with IPT	


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	9	11
Available funding (US\$ millions)	5	9
% of budget funded	58	81
% available funding from domestic sources	7	4
% available funding from Global Fund	69	53

NTP Budget (blue) and available funding (green) (US\$ millions)



BANGLADESH

POPULATION 2010 (MILLIONS) **149**

ESTIMATES OF BURDEN 2010 ^a	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	64 (47–85)	43 (32–57)
Prevalence (incl HIV)	610 (280–1 000)	411 (188–671)
Incidence (incl HIV)	330 (270–400)	225 (184–269)
Incidence (HIV-positive)	0.66 (0.33–1.1)	0.45 (0.23–0.74)
Case detection, all forms (%)	46 (38–56)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	105 772 (70)	Relapse	2 989 (38)
Smear-negative	21 625 (14)	Treatment after failure	961 (12)
Smear unknown	0 (0)	Treatment after default	594 (8)
Extrapulmonary	23 506 (16)	Other	3 251 (42)
Other	0 (0)		
Total new	150 903	Total retreatment	7 795
Total < 15 years	4 235		
Total new and relapse		153 892	(97% of total)
Total cases notified		158 698	


DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	100
Paediatric formulations procured	Yes

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	92
New smear-negative/extrapulmonary	89
Retreatment	81

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	2.1 (1.7–2.5)
% of retreatment TB cases with MDR-TB	28 (25–32)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	2 700 (2 200–3 200)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	2 200 (1 900–2 500)

MDR-TB REPORTED CASES 2010

	New	Retreatment	Total
Cases tested for MDR-TB		339	339
% of notified tested for MDR-TB		4	<1
Confirmed cases of MDR-TB		339	339
MDR-TB patients started treatment		339	339

LABORATORIES


	2009	2010	2011
Smear (per 100 000 population)	0.7	0.7	0.7
Culture (per 5 million population)	<0.1	0.1	0.1
DST (per 5 million population)	<0.1	<0.1	<0.1

Second-line DST available	Outside country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV

(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	1 778
% of TB patients with known HIV status	1
TB patients that are HIV-positive	4
% of tested TB patients that are HIV-positive	<1
% HIV-positive TB patients started on CPT	100
% HIV-positive TB patients started on ART	0
HIV-positive people screened for TB	347
HIV-positive people provided with IPT	64


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	41	48
Available funding (US\$ millions)	12	14
% of budget funded	29	28
% available funding from domestic sources	10	9
% available funding from Global Fund	57	75

NTP Budget (blue) and available funding (green) (US\$ millions)



BRAZIL

POPULATION 2010 (MILLIONS) **195**

ESTIMATES OF BURDEN 2010 ^a	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	5 (3.1–8.3)	2.6 (1.6–4.3)
Prevalence (incl HIV)	92 (34–160)	47 (17–80)
Incidence (incl HIV)	85 (70–100)	43 (36–51)
Incidence (HIV-positive)	18 (15–22)	9.3 (7.7–11)
Case detection, all forms (%)	88 (74–110)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	37 932 (53)	Relapse	3 398 (31)
Smear-negative	13 694 (19)	Treatment after failure	122 (1)
Smear unknown	9 336 (13)	Treatment after default	3 208 (29)
Extrapulmonary	10 017 (14)	Other	4 221 (39)
Other	18 (<1)		
Total new	70 997	Total retreatment	10 949
Total < 15 years	2 450		

Total new and relapse	74 395	(91% of total)
Total cases notified	81 946	


DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	100
Paediatric formulations procured	No

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	72
New smear-negative/extrapulmonary	68
Retreatment	42

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	0.90 (0.60–1.4)
% of retreatment TB cases with MDR-TB	5.4 (3.9–7.3)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	550 (370–850)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	590 (450–800)

MDR-TB REPORTED CASES 2010	New	Retreatment	Total
Cases tested for MDR-TB	22	643	665
% of notified tested for MDR-TB	<1	6	<1
Confirmed cases of MDR-TB	21	552	573
MDR-TB patients started treatment			573


LABORATORIES	2009	2010	2011
Smear (per 100 000 population)	2.1	2.0	2.0
Culture (per 5 million population)	5.8	6.5	6.9
DST (per 5 million population)	1.1	1.0	1.1

Second-line DST available	In and outside country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	37 210
% of TB patients with known HIV status	45
TB patients that are HIV-positive	8 558
% of tested TB patients that are HIV-positive	23
% HIV-positive TB patients started on CPT	
% HIV-positive TB patients started on ART	93
HIV-positive people screened for TB	
HIV-positive people provided with IPT	


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	87	87
Available funding (US\$ millions)	80	74
% of budget funded	92	85
% available funding from domestic sources	90	97
% available funding from Global Fund	5	1

NTP Budget (blue) and available funding (green) (US\$ millions)



CAMBODIA

POPULATION 2010 (MILLIONS) **14**

ESTIMATES OF BURDEN 2010 ^a	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	8.6 (6.2–12)	61 (44–82)
Prevalence (incl HIV)	93 (42–150)	660 (296–1070)
Incidence (incl HIV)	62 (53–72)	437 (373–506)
Incidence (HIV-positive)	4 (3.4–4.7)	29 (24–33)
Case detection, all forms (%)	65 (57–77)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	17 454 (44)	Relapse	466 (29)
Smear-negative	8 301 (21)	Treatment after failure	59 (4)
Smear unknown	0 (0)	Treatment after default	19 (1)
Extrapulmonary	14 239 (36)	Other	1 090 (67)
Other	0 (0)		
Total new	39 994	Total retreatment	1 634
Total < 15 years	99		

Total new and relapse	40 460	(97% of total)
Total cases notified	41 628	


DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	100
Paediatric formulations procured	Yes

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	95
New smear-negative/extrapulmonary	93
Retreatment	79

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	1.4 (0.70–2.5)
% of retreatment TB cases with MDR-TB	11 (4.0–22)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	360 (180–640)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	170 (65–360)

MDR-TB REPORTED CASES 2010	New	Retreatment	Total
Cases tested for MDR-TB	5	93	98
% of notified tested for MDR-TB	<1	6	<1
Confirmed cases of MDR-TB	1	30	31
MDR-TB patients started treatment			38

LABORATORIES


	2009	2010	2011
Smear (per 100 000 population)	1.5	1.5	1.5
Culture (per 5 million population)	1.1	1.1	1.0
DST (per 5 million population)	0.4	0.4	0.3

Second-line DST available	Outside country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	32 236
% of TB patients with known HIV status	77
TB patients that are HIV-positive	2 112
% of tested TB patients that are HIV-positive	7
% HIV-positive TB patients started on CPT	65
% HIV-positive TB patients started on ART	45
HIV-positive people screened for TB	
HIV-positive people provided with IPT	491


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	39	40
Available funding (US\$ millions)	14	15
% of budget funded	35	36
% available funding from domestic sources	8	8
% available funding from Global Fund	36	31

NTP Budget (blue) and available funding (green) (US\$ millions)



CHINA

POPULATION 2010 (MILLIONS) **1 341**

ESTIMATES OF BURDEN 2010 ^a	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	54 (52–56)	4.1 (3.9–4.2)
Prevalence (incl HIV)	1 500 (1 300–1 700)	108 (93–123)
Incidence (incl HIV)	1 000 (910–1 200)	78 (68–88)
Incidence (HIV-positive)	18 (10–28)	1.4 (0.77–2.1)
Case detection, all forms (%)	87 (77–100)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	429 899 (49)	Relapse	39 307 (73)
Smear-negative	430 580 (50)	Treatment after failure	2 662 (5)
Smear unknown	2 288 (<1)	Treatment after default	1 103 (2)
Extrapulmonary	6 325 (<1)	Other	11 144 (21)
Other	0 (0)		
Total new	869 092	Total retreatment	54 216
Total < 15 years	6 710		

Total new and relapse	908 399	(98% of total)
Total cases notified	923 308	


DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	15
Paediatric formulations procured	No

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	95
New smear-negative/extrapulmonary	92
Retreatment	90

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	5.7 (4.6–7.1)
% of retreatment TB cases with MDR-TB	26 (22–30)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	49 000 (40 000–61 000)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	14 000 (12 000–16 000)

MDR-TB REPORTED CASES 2010	New	Retreatment	Total
Cases tested for MDR-TB			
% of notified tested for MDR-TB			
Confirmed cases of MDR-TB	229	1 669	2 792
MDR-TB patients started treatment			1 222


LABORATORIES	2009	2010	2011
Smear (per 100 000 population)	0.2	0.2	0.2
Culture (per 5 million population)	3.1	3.3	2.7
DST (per 5 million population)	0.5	0.7	0.8

Second-line DST available	In country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	145 919
% of TB patients with known HIV status	16
TB patients that are HIV-positive	4 542
% of tested TB patients that are HIV-positive	3
% HIV-positive TB patients started on CPT	
% HIV-positive TB patients started on ART	45
HIV-positive people screened for TB	65 412
HIV-positive people provided with IPT	


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	285	350
Available funding (US\$ millions)	278	319
% of budget funded	98	91
% available funding from domestic sources	70	69
% available funding from Global Fund	30	30

NTP Budget (blue) and available funding (green) (US\$ millions)



DEMOCRATIC REPUBLIC OF THE CONGO

POPULATION 2010 (MILLIONS) **66**

ESTIMATES OF BURDEN 2010 ^a	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	36 (27-45)	54 (41-69)
Prevalence (incl HIV)	350 (160-560)	535 (250-850)
Incidence (incl HIV)	220 (190-250)	327 (281-376)
Incidence (HIV-positive)	18 (13-24)	27 (19-36)
Case detection, all forms (%)	53 (46-61)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	73 653 (67)	Relapse	4 138 (48)
Smear-negative	14 039 (13)	Treatment after failure	713 (8)
Smear unknown	0 (0)	Treatment after default	796 (9)
Extrapulmonary	22 340 (20)	Other	2 957 (34)
Other	0 (0)		
Total new	110 032	Total retreatment	8 604
Total < 15 years	3 694		

Total new and relapse	114 170	(96% of total)
Total cases notified	118 636	


DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	100
Paediatric formulations procured	Yes

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	88
New smear-negative/extrapulmonary	86
Retreatment	77

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	2.2 (0.10-5.3)
% of retreatment TB cases with MDR-TB	9.4 (1.9-17)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	1 900 (88-4 600)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	810 (160-1 500)

MDR-TB REPORTED CASES 2010	New	Retreatment	Total
Cases tested for MDR-TB		100	100
% of notified tested for MDR-TB		1	<1
Confirmed cases of MDR-TB		87	87
MDR-TB patients started treatment			191


LABORATORIES	2009	2010	2011
Smear (per 100 000 population)	2.2	2.2	2.2
Culture (per 5 million population)	<0.1	<0.1	0.1
DST (per 5 million population)	<0.1	<0.1	0.1

Second-line DST available	No
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	28 997
% of TB patients with known HIV status	24
TB patients that are HIV-positive	5 273
% of tested TB patients that are HIV-positive	18
% HIV-positive TB patients started on CPT	24
% HIV-positive TB patients started on ART	9
HIV-positive people screened for TB	3 892
HIV-positive people provided with IPT	


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	64	62
Available funding (US\$ millions)	<1	
% of budget funded	1	
% available funding from domestic sources	0	
% available funding from Global Fund	0	

NTP Budget (blue) and available funding (green) (US\$ millions)



ETHIOPIA

POPULATION 2010 (MILLIONS) **83**

ESTIMATES OF BURDEN 2010 ^a	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	29 (23–35)	35 (28–42)
Prevalence (incl HIV)	330 (140–520)	394 (173–623)
Incidence (incl HIV)	220 (200–230)	261 (240–282)
Incidence (HIV-positive)		
Case detection, all forms (%)	72 (66–78)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	46 634 (31)	Relapse	2 664 (54)
Smear-negative	52 457 (35)	Treatment after failure	493 (10)
Smear unknown	2 522 (2)	Treatment after default	777 (16)
Extrapulmonary	50 417 (33)	Other	964 (20)
Other	0 (0)		
Total new	152 030	Total retreatment	4 898
Total < 15 years	3 190		

Total new and relapse	154 694	(99% of total)
Total cases notified	156 928	


DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	100
Paediatric formulations procured	Yes

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	84
New smear-negative/extrapulmonary	80
Retreatment	67

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	1.6 (0.90–2.8)
% of retreatment TB cases with MDR-TB	12 (5.6–21)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	1 600 (910–2 800)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	580 (270–1 000)

MDR-TB REPORTED CASES 2010	New	Retreatment	Total
Cases tested for MDR-TB	42	510	558
% of notified tested for MDR-TB	<1	10	<1
Confirmed cases of MDR-TB	19	121	140
MDR-TB patients started treatment			120


LABORATORIES	2009	2010	2011
Smear (per 100 000 population)	1.5	2.3	2.8
Culture (per 5 million population)	0.1	0.1	0.4
DST (per 5 million population)	0.1	0.1	0.1

Second-line DST available	In country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	66 955
% of TB patients with known HIV status	43
TB patients that are HIV-positive	9 809
% of tested TB patients that are HIV-positive	15
% HIV-positive TB patients started on CPT	69
% HIV-positive TB patients started on ART	39
HIV-positive people screened for TB	43 837
HIV-positive people provided with IPT	6 636


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	49	52
Available funding (US\$ millions)	40	38
% of budget funded	83	74
% available funding from domestic sources	20	23
% available funding from Global Fund	40	39

NTP Budget (blue) and available funding (green) (US\$ millions)



INDIA

POPULATION 2010 (MILLIONS) 1 225

ESTIMATES OF BURDEN 2010 ^a	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	320 (210–470)	26 (17–39)
Prevalence (incl HIV)	3 100 (2 000–4 600)	256 (161–373)
Incidence (incl HIV)	2 300 (2 000–2 500)	185 (167–205)
Incidence (HIV-positive)	110 (75–160)	9.2 (6.1–13)
Case detection, all forms (%)	59 (53–65)	

CASE NOTIFICATIONS 2010

New cases (%)		Retreatment cases (%)	
Smear-positive	630 165 (51)	Relapse	110 691 (38)
Smear-negative	366 381 (30)	Treatment after failure	18 463 (6)
Smear unknown		Treatment after default	72 110 (25)
Extrapulmonary	231 121 (19)	Other	91 708 (31)
Other	1 508 (<1)		
Total new	1 229 175	Total retreatment	292 972
Total < 15 years	13 415		

Total new and relapse	1 339 866	(88% of total)
Total cases notified	1 522 147	


DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	0
Paediatric formulations procured	Yes

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	88
New smear-negative/extrapulmonary	90
Retreatment	75

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	2.1 (1.5–2.7)
% of retreatment TB cases with MDR-TB	15 (13–17)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	21 000 (15 000–27 000)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	43 000 (39 000–48 000)

MDR-TB REPORTED CASES 2010	New	Retreatment	Total
Cases tested for MDR-TB			
% of notified tested for MDR-TB			
Confirmed cases of MDR-TB			2 967
MDR-TB patients started treatment			2 967


LABORATORIES	2009	2010	2011
Smear (per 100 000 population)	1.1	1.1	1.0
Culture (per 5 million population)	<0.1	<0.1	0.1
DST (per 5 million population)	<0.1	<0.1	0.1

Second-line DST available	In country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals. Estimates for India have not yet been officially approved by the Ministry of Health & Family Welfare, Government of India and should therefore be considered provisional.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	480 752
% of TB patients with known HIV status	32
TB patients that are HIV-positive	41 476
% of tested TB patients that are HIV-positive	9
% HIV-positive TB patients started on CPT	90
% HIV-positive TB patients started on ART	57
HIV-positive people screened for TB	199 732
HIV-positive people provided with IPT	


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	139	210
Available funding (US\$ millions)	139	210
% of budget funded	100	100
% available funding from domestic sources	44	62
% available funding from Global Fund	49	38

NTP Budget (blue) and available funding (green) (US\$ millions)



INDONESIA

POPULATION 2010 (MILLIONS) **240**

ESTIMATES OF BURDEN 2010 ^a	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	64 (42–91)	27 (18–38)
Prevalence (incl HIV)	690 (300–1 200)	289 (123–484)
Incidence (incl HIV)	450 (370–540)	189 (155–226)
Incidence (HIV-positive)	18 (9.9–29)	7.6 (4.1–12)
Case detection, all forms (%)	66 (55–81)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	183 366 (62)	Relapse	4 387 (67)
Smear-negative	101 247 (34)	Treatment after failure	327 (5)
Smear unknown	0 (0)	Treatment after default	862 (13)
Extrapulmonary	11 659 (4)	Other	1 013 (15)
Other	0 (0)		
Total new	296 272	Total retreatment	6 589
Total < 15 years	28 312		

Total new and relapse	300 659	(99% of total)
Total cases notified	302 861	


DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	100
Paediatric formulations procured	Yes

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	91
New smear-negative/extrapulmonary	87
Retreatment	72

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	1.8 (1.1–2.7)
% of retreatment TB cases with MDR-TB	17 (8.1–26)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	5 100 (3 100–7 700)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	1 100 (530–1 700)

MDR-TB REPORTED CASES 2010	New	Retreatment	Total
Cases tested for MDR-TB	0	324	324
% of notified tested for MDR-TB	0	5	<1
Confirmed cases of MDR-TB	0	182	182
MDR-TB patients started treatment			142

LABORATORIES


	2009	2010	2011
Smear (per 100 000 population)	2.2	2.1	2.9
Culture (per 5 million population)	0.9	0.9	0.9
DST (per 5 million population)	0.1	0.1	0.2

Second-line DST available	In country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	
% of TB patients with known HIV status	
TB patients that are HIV-positive	
% of tested TB patients that are HIV-positive	
% HIV-positive TB patients started on CPT	
% HIV-positive TB patients started on ART	
HIV-positive people screened for TB	3 217
HIV-positive people provided with IPT	


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	91	102
Available funding (US\$ millions)	43	63
% of budget funded	48	62
% available funding from domestic sources	31	26
% available funding from Global Fund	68	74

NTP Budget (blue) and available funding (green) (US\$ millions)



KENYA

POPULATION 2010 (MILLIONS) **41**

ESTIMATES OF BURDEN 2010 ^a	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	6.9 (4.9–9.4)	17 (12–23)
Prevalence (incl HIV)	110 (49–180)	283 (122–448)
Incidence (incl HIV)	120 (120–130)	298 (286–311)
Incidence (HIV-positive)	50 (45–55)	122 (110–135)
Case detection, all forms (%)	82 (79–86)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	36 260 (38)	Relapse	3 668 (35)
Smear-negative	31 842 (33)	Treatment after failure	245 (2)
Smear unknown	10 120 (11)	Treatment after default	1 502 (14)
Extrapulmonary	17 382 (18)	Other	5 064 (48)
Other	0 (0)		
Total new	95 604	Total retreatment	10 479
Total < 15 years	5 721		

Total new and relapse	99 272	(94% of total)
Total cases notified	106 083	


DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	100
Paediatric formulations procured	Yes

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	86
New smear-negative/extrapulmonary	82
Retreatment	78

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	0.0 (0.0–0.70)
% of retreatment TB cases with MDR-TB	0.0 (0.0–6.3)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	0 (0–550)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	0 (0–660)

MDR-TB REPORTED CASES 2010

	New	Retreatment	Total
Cases tested for MDR-TB		706	817
% of notified tested for MDR-TB		7	<1
Confirmed cases of MDR-TB		103	112
MDR-TB patients started treatment			118

LABORATORIES


	2009	2010	2011
Smear (per 100 000 population)	3.0	3.3	3.2
Culture (per 5 million population)	0.8	0.7	0.7
DST (per 5 million population)	0.5	0.5	0.6

Second-line DST available	Outside country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	96 930
% of TB patients with known HIV status	91
TB patients that are HIV-positive	40 069
% of tested TB patients that are HIV-positive	41
% HIV-positive TB patients started on CPT	100
% HIV-positive TB patients started on ART	48
HIV-positive people screened for TB	
HIV-positive people provided with IPT	


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	59	53
Available funding (US\$ millions)	30	20
% of budget funded	51	38
% available funding from domestic sources	37	39
% available funding from Global Fund	49	59

NTP Budget (blue) and available funding (green) (US\$ millions)



MOZAMBIQUE

POPULATION 2010 (MILLIONS)

23

ESTIMATES OF BURDEN 2010^a

	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	11 (7–17)	49 (30–74)
Prevalence (incl HIV)	110 (54–200)	491 (233–844)
Incidence (incl HIV)	130 (87–170)	544 (374–746)
Incidence (HIV-positive)	77 (53–110)	330 (228–449)
Case detection, all forms (%)	34 (25–50)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	20 097 (48)	Relapse	1 432 (35)
Smear-negative	16 408 (39)	Treatment after failure	234 (6)
Smear unknown	0 (0)	Treatment after default	235 (6)
Extrapulmonary	5 621 (13)	Other	2 147 (53)
Other	0 (0)		
Total new	42 126	Total retreatment	4 048
Total < 15 years			
Total new and relapse			
	43 558		(94% of total)
Total cases notified			
	46 174		


DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	95
Paediatric formulations procured	Yes

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	85
New smear-negative/extrapulmonary	
Retreatment	

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	3.5 (2.2–4.8)
% of retreatment TB cases with MDR-TB	11 (0.0–25)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	1 300 (800–1 800)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	450 (0–1 000)

MDR-TB REPORTED CASES 2010

	New	Retreatment	Total
Cases tested for MDR-TB	80	251	365
% of notified tested for MDR-TB	<1	6	<1
Confirmed cases of MDR-TB	18	130	165
MDR-TB patients started treatment			87

LABORATORIES

	2009	2010	2011
Smear (per 100 000 population)	1.9	1.9	1.8
Culture (per 5 million population)	0.2	0.4	0.6
DST (per 5 million population)	0.2	0.4	0.6

Second-line DST available	Outside country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	40 554
% of TB patients with known HIV status	88
TB patients that are HIV-positive	24 574
% of tested TB patients that are HIV-positive	61
% HIV-positive TB patients started on CPT	97
% HIV-positive TB patients started on ART	25
HIV-positive people screened for TB	433
HIV-positive people provided with IPT	8 904


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	34	39
Available funding (US\$ millions)	24	24
% of budget funded	71	62
% available funding from domestic sources	11	11
% available funding from Global Fund	0	12

NTP Budget (blue) and available funding (green) (US\$ millions)



MYANMAR

POPULATION 2010 (MILLIONS) **48**

ESTIMATES OF BURDEN 2010 ^a	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	20 (12–31)	41 (25–64)
Prevalence (incl HIV)	250 (180–310)	525 (381–643)
Incidence (incl HIV)	180 (160–210)	384 (329–443)
Incidence (HIV-positive)	37 (21–57)	77 (43–120)
Case detection, all forms (%)	71 (62–84)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	42 318 (33)	Relapse	4 456 (43)
Smear-negative	56 840 (45)	Treatment after failure	1 495 (15)
Smear unknown		Treatment after default	514 (5)
Extrapulmonary	27 976 (22)	Other	3 804 (37)
Other			
Total new	127 134	Total retreatment	10 269
Total < 15 years	302		
Total new and relapse	131 590		(96% of total)
Total cases notified	137 403		


DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	100
Paediatric formulations procured	Yes

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	85
New smear-negative/extrapulmonary	83
Retreatment	73

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	4.2 (3.1–5.6)
% of retreatment TB cases with MDR-TB	10 (6.9–14)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	4 200 (3 100–5 600)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	1 000 (710–1 400)

MDR-TB REPORTED CASES 2010	New	Retreatment	Total
Cases tested for MDR-TB			
% of notified tested for MDR-TB			
Confirmed cases of MDR-TB			192
MDR-TB patients started treatment			192

LABORATORIES


	2009	2010	2011
Smear (per 100 000 population)	0.9	0.9	0.9
Culture (per 5 million population)	0.2	0.2	0.3
DST (per 5 million population)	0.2	0.2	0.2

Second-line DST available	Outside country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV

(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	4 362
% of TB patients with known HIV status	3
TB patients that are HIV-positive	961
% of tested TB patients that are HIV-positive	22
% HIV-positive TB patients started on CPT	100
% HIV-positive TB patients started on ART	94
HIV-positive people screened for TB	6 417
HIV-positive people provided with IPT	514


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	31	29
Available funding (US\$ millions)	14	11
% of budget funded	45	37
% available funding from domestic sources	4	6
% available funding from Global Fund	46	75

NTP Budget (blue) and available funding (green) (US\$ millions)



NIGERIA

POPULATION 2010 (MILLIONS) **158**

ESTIMATES OF BURDEN 2010 ^a	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	33 (11–68)	21 (7.2–43)
Prevalence (incl HIV)	320 (110–690)	199 (70–438)
Incidence (incl HIV)	210 (99–360)	133 (63–228)
Incidence (HIV-positive)	51 (25–87)	32 (16–55)
Case detection, all forms (%)	40 (23–85)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	45 416 (56)	Relapse	2 667 (30)
Smear-negative	32 616 (40)	Treatment after failure	748 (8)
Smear unknown	0 (0)	Treatment after default	1 650 (18)
Extrapulmonary	3 422 (4)	Other	3 928 (44)
Other	0 (0)		
Total new	81 454	Total retreatment	8 993
Total < 15 years	1 116		

Total new and relapse	84 121	(93% of total)
Total cases notified	90 447	


DRUG REGIMENS

Rifampicin used throughout treatment	No
% of patients treated with fixed-dose combinations (FDCs)	100
Paediatric formulations procured	Yes

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	83
New smear-negative/extrapulmonary	85
Retreatment	81

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	2.2 (0.10–5.3)
% of retreatment TB cases with MDR-TB	9.4 (1.9–17)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	1 700 (78–4 100)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	850 (170–1 500)

MDR-TB REPORTED CASES 2010	New	Retreatment	Total
Cases tested for MDR-TB	27	19	55
% of notified tested for MDR-TB	<1	<1	<1
Confirmed cases of MDR-TB	8	11	21
MDR-TB patients started treatment			23


LABORATORIES	2009	2010	2011
Smear (per 100 000 population)	0.7	0.6	0.9
Culture (per 5 million population)	0.1	0.2	0.2
DST (per 5 million population)	<0.1	0.1	0.2

Second-line DST available	Outside country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	71 844
% of TB patients with known HIV status	79
TB patients that are HIV-positive	17 736
% of tested TB patients that are HIV-positive	25
% HIV-positive TB patients started on CPT	59
% HIV-positive TB patients started on ART	33
HIV-positive people screened for TB	57 082
HIV-positive people provided with IPT	1 750


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	39	43
Available funding (US\$ millions)	28	26
% of budget funded	73	61
% available funding from domestic sources	21	25
% available funding from Global Fund	54	48

NTP Budget (blue) and available funding (green) (US\$ millions)



PAKISTAN

POPULATION 2010 (MILLIONS) 174

ESTIMATES OF BURDEN 2010 ^a	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	58 (39–84)	34 (22–49)
Prevalence (incl HIV)	630 (270–1 100)	364 (154–611)
Incidence (incl HIV)	400 (330–480)	231 (189–277)
Incidence (HIV-positive)	1.2 (0.66–1.9)	0.69 (0.38–1.1)
Case detection, all forms (%)	65 (54–79)	

CASE NOTIFICATIONS 2010

New cases (%)	Retreatment cases (%)
Smear-positive 104 263 (41)	Relapse 5 870 (54)
Smear-negative 105 623 (41)	Treatment after failure 1 003 (9)
Smear unknown 0 (0)	Treatment after default 1 527 (14)
Extrapulmonary 45 443 (18)	Other 2 525 (23)
Other 0 (0)	
Total new 255 329	Total retreatment 10 925
Total < 15 years 24 474	

Total new and relapse	261 199	(97% of total)
Total cases notified	269 290	


DRUG REGIMENS

Rifampicin used throughout treatment	No
% of patients treated with fixed-dose combinations (FDCs)	100
Paediatric formulations procured	Yes

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	91
New smear-negative/extrapulmonary	90
Retreatment	82

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	3.4 (0.80–6.0)
% of retreatment TB cases with MDR-TB	21 (7.3–34)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	7 100 (1 700–13 000)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	2 300 (800–3 700)

MDR-TB REPORTED CASES 2010	New	Retreatment	Total
Cases tested for MDR-TB	9	306	444
% of notified tested for MDR-TB	<1	3	<1
Confirmed cases of MDR-TB	9	306	444
MDR-TB patients started treatment			424


LABORATORIES	2009	2010	2011
Smear (per 100 000 population)	0.7	0.7	0.7
Culture (per 5 million population)	0.4	0.4	0.4
DST (per 5 million population)	0.3	0.3	0.3

Second-line DST available	In country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	6 289
% of TB patients with known HIV status	2
TB patients that are HIV-positive	22
% of tested TB patients that are HIV-positive	<1
% HIV-positive TB patients started on CPT	
% HIV-positive TB patients started on ART	9
HIV-positive people screened for TB	
HIV-positive people provided with IPT	


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	60	64
Available funding (US\$ millions)	13	11
% of budget funded	22	18
% available funding from domestic sources	34	25
% available funding from Global Fund	41	50

NTP Budget (blue) and available funding (green) (US\$ millions)



PHILIPPINES

POPULATION 2010 (MILLIONS)

93

ESTIMATES OF BURDEN 2010^a

	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	31 (21–43)	33 (22–46)
Prevalence (incl HIV)	470 (410–530)	502 (438–566)
Incidence (incl HIV)	260 (210–310)	275 (226–329)
Incidence (HIV-positive)	1 (0.51–1.8)	1.1 (0.55–1.9)
Case detection, all forms (%)	65 (54–79)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	89 198 (55)	Relapse	3 075 (28)
Smear-negative	72 440 (44)	Treatment after failure	566 (5)
Smear unknown	0 (0)	Treatment after default	914 (8)
Extrapulmonary	1 610 (<1)	Other	6 586 (59)
Other	0 (0)		
Total new	163 248	Total retreatment	11 141
Total < 15 years	965		
Total new and relapse	166 323		(95% of total)
Total cases notified	174 389		

DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	100
Paediatric formulations procured	Yes

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	89
New smear-negative/extrapulmonary	79
Retreatment	61

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	4.0 (2.9–5.5)
% of retreatment TB cases with MDR-TB	21 (14–29)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	6 500 (4 700–8 900)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	2 300 (1 600–3 200)

MDR-TB REPORTED CASES 2010

	New	Retreatment	Total
Cases tested for MDR-TB	3	297	300
% of notified tested for MDR-TB	<1	3	<1
Confirmed cases of MDR-TB	2	232	522
MDR-TB patients started treatment			548

LABORATORIES


	2009	2010	2011
Smear (per 100 000 population)	2.2	2.1	2.1
Culture (per 5 million population)	0.5	0.4	1.4
DST (per 5 million population)	0.2	0.1	0.2

Second-line DST available	In country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	1 356
% of TB patients with known HIV status	<1
TB patients that are HIV-positive	0
% of tested TB patients that are HIV-positive	0
% HIV-positive TB patients started on CPT	
% HIV-positive TB patients started on ART	
HIV-positive people screened for TB	119
HIV-positive people provided with IPT	16


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	81	79
Available funding (US\$ millions)	55	48
% of budget funded	67	60
% available funding from domestic sources	55	51
% available funding from Global Fund	42	49

NTP Budget (blue) and available funding (green) (US\$ millions)



RUSSIAN FEDERATION

POPULATION 2010 (MILLIONS) **143**

ESTIMATES OF BURDEN 2010 ^a	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	26 (16–42)	18 (11–29)
Prevalence (incl HIV)	190 (70–330)	136 (49–233)
Incidence (incl HIV)	150 (130–180)	106 (90–124)
Incidence (HIV-positive)	8.1 (6.8–9.4)	5.7 (4.8–6.6)
Case detection, all forms (%)	78 (67–93)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	31 416 (29)	Relapse	8 737 (19)
Smear-negative	66 595 (61)	Treatment after failure	8 197 (18)
Smear unknown	1 299 (1)	Treatment after default	2 897 (6)
Extrapulmonary	3 513 (3)	Other	26 149 (57)
Other	7 081 (6)		
Total new	109 904	Total retreatment	45 980
Total < 15 years	831		

Total new and relapse	118 641	(73% of total)
Total cases notified	162 553	


DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	
Paediatric formulations procured	No

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	55
New smear-negative/extrapulmonary	73
Retreatment	34

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	18 (16–19)
% of retreatment TB cases with MDR-TB	46 (41–52)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	19 000 (17 000–20 000)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	21 000 (19 000–24 000)

MDR-TB REPORTED CASES 2010

	New	Retreatment	Total
Cases tested for MDR-TB	35 862	13 405	49 267
% of notified tested for MDR-TB	33	29	30
Confirmed cases of MDR-TB	6 218	6 169	13 692
MDR-TB patients started treatment			13 692

LABORATORIES


	2009	2010	2011
Smear (per 100 000 population)	2.8	2.8	
Culture (per 5 million population)	13.9	13.9	
DST (per 5 million population)	9.5	9.5	

Second-line DST available	In country
National Reference Laboratory	No

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	199 445
% of TB patients with known HIV status	123
TB patients that are HIV-positive	10 617
% of tested TB patients that are HIV-positive	5
% HIV-positive TB patients started on CPT	
% HIV-positive TB patients started on ART	82
HIV-positive people screened for TB	
HIV-positive people provided with IPT	


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	1 216	1 204
Available funding (US\$ millions)	1 216	1 204
% of budget funded	100	100
% available funding from domestic sources	100	100
% available funding from Global Fund	0	0

NTP Budget (blue) and available funding (green) (US\$ millions)



SOUTH AFRICA

POPULATION 2010 (MILLIONS) **50**

ESTIMATES OF BURDEN 2010 ^a	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	25 (16–38)	50 (31–75)
Prevalence (incl HIV)	400 (180–630)	795 (364–1 264)
Incidence (incl HIV)	490 (400–590)	981 (806–1 173)
Incidence (HIV-positive)	300 (240–350)	591 (488–704)
Case detection, all forms (%)	72 (60–88)	

CASE NOTIFICATIONS 2010

New cases (%)		Retreatment cases (%)	
Smear-positive	132 107 (39)	Relapse	18 812 (31)
Smear-negative	64 692 (19)	Treatment after failure	2 671 (4)
Smear unknown	87 080 (26)	Treatment after default	4 921 (8)
Extrapulmonary	52 095 (16)	Other	34 176 (56)
Other	0 (0)		
Total new	335 974	Total retreatment	60 580
Total < 15 years	50 474		

Total new and relapse	354 786	(89% of total)
Total cases notified	396 554	


DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	100
Paediatric formulations procured	Yes

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	73
New smear-negative/extrapulmonary	64
Retreatment	60

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	1.8 (1.4–2.3)
% of retreatment TB cases with MDR-TB	6.7 (5.4–8.2)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	5 100 (4 000–6 500)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	4 100 (3 300–5 000)

MDR-TB REPORTED CASES 2010	New	Retreatment	Total
Cases tested for MDR-TB			92 300
% of notified tested for MDR-TB			23
Confirmed cases of MDR-TB			7 386
MDR-TB patients started treatment			5 402


LABORATORIES	2009	2010	2011
Smear (per 100 000 population)	0.5	0.5	0.5
Culture (per 5 million population)	1.6	1.5	1.5
DST (per 5 million population)	1.6	1.5	1.5

Second-line DST available	In country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	213 006
% of TB patients with known HIV status	54
TB patients that are HIV-positive	128 457
% of tested TB patients that are HIV-positive	60
% HIV-positive TB patients started on CPT	74
% HIV-positive TB patients started on ART	54
HIV-positive people screened for TB	758 837
HIV-positive people provided with IPT	124 049


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	218	
Available funding (US\$ millions)	218	
% of budget funded	100	
% available funding from domestic sources	100	
% available funding from Global Fund	0	

NTP Budget (blue) and available funding (green) (US\$ millions)



THAILAND

POPULATION 2010 (MILLIONS)

69

ESTIMATES OF BURDEN 2010^a

	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	11 (7–16)	16 (10–23)
Prevalence (incl HIV)	130 (55–210)	182 (80–300)
Incidence (incl HIV)	94 (78–110)	137 (112–163)
Incidence (HIV-positive)	15 (13–18)	22 (18–27)
Case detection, all forms (%)	70 (59–85)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	33 450 (52)	Relapse	1 885 (63)
Smear-negative	20 927 (32)	Treatment after failure	459 (15)
Smear unknown		Treatment after default	652 (22)
Extrapulmonary	10 135 (16)	Other	0 (0)
Other	0 (0)		
Total new	64 512	Total retreatment	2 996
Total < 15 years	137		

Total new and relapse	66 397	(97% of total)
Total cases notified	68 239	


DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	25
Paediatric formulations procured	No

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	86
New smear-negative/extrapulmonary	80
Retreatment	68

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	1.7 (1.0–2.6)
% of retreatment TB cases with MDR-TB	35 (28–42)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	920 (540–1 400)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	1 000 (840–1 200)

MDR-TB REPORTED CASES 2010

	New	Retreatment	Total
Cases tested for MDR-TB			
% of notified tested for MDR-TB			
Confirmed cases of MDR-TB			
MDR-TB patients started treatment			9

LABORATORIES


	2009	2010	2011
Smear (per 100 000 population)	1.6	1.6	1.6
Culture (per 5 million population)	4.7	4.7	4.7
DST (per 5 million population)	1.1	1.1	1.2

Second-line DST available	In country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	52 753
% of TB patients with known HIV status	77
TB patients that are HIV-positive	8 544
% of tested TB patients that are HIV-positive	16
% HIV-positive TB patients started on CPT	71
% HIV-positive TB patients started on ART	53
HIV-positive people screened for TB	25 278
HIV-positive people provided with IPT	


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	45	45
Available funding (US\$ millions)	42	42
% of budget funded	92	92
% available funding from domestic sources	81	81
% available funding from Global Fund	8	8

NTP Budget (blue) and available funding (green) (US\$ millions)



UGANDA

POPULATION 2010 (MILLIONS)

33

ESTIMATES OF BURDEN 2010^a

	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	5.1 (3.3–7.3)	15 (9.9–22)
Prevalence (incl HIV)	64 (32–100)	193 (95–306)
Incidence (incl HIV)	70 (56–85)	209 (168–254)
Incidence (HIV-positive)	38 (30–46)	112 (91–136)
Case detection, all forms (%)	61 (51–76)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	23 456 (56)	Relapse	1 291 (33)
Smear-negative	11 609 (28)	Treatment after failure	264 (7)
Smear unknown	1 958 (5)	Treatment after default	1 209 (31)
Extrapulmonary	4 571 (11)	Other	1 188 (30)
Other	0 (0)		
Total new	41 594	Total retreatment	3 952
Total < 15 years	669		

Total new and relapse	42 885	(94% of total)
Total cases notified	45 546	


DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	100
Paediatric formulations procured	Yes

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	67
New smear-negative/extrapulmonary	59
Retreatment	70

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	1.1 (0.30–2.5)
% of retreatment TB cases with MDR-TB	12 (4.8–23)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	410 (110–930)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	46 (190–890)

MDR-TB REPORTED CASES 2010

	New	Retreatment	Total
Cases tested for MDR-TB	358	356	1 623
% of notified tested for MDR-TB	<1	9	4
Confirmed cases of MDR-TB	15	37	93
MDR-TB patients started treatment			10

LABORATORIES


	2009	2010	2011
Smear (per 100 000 population)	2.6	2.9	2.8
Culture (per 5 million population)	0.9	1.2	1.2
DST (per 5 million population)	0.6	0.6	0.6

Second-line DST available	In country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	36 724
% of TB patients with known HIV status	81
TB patients that are HIV-positive	19 836
% of tested TB patients that are HIV-positive	54
% HIV-positive TB patients started on CPT	90
% HIV-positive TB patients started on ART	24
HIV-positive people screened for TB	401 973
HIV-positive people provided with IPT	


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	23	20
Available funding (US\$ millions)	11	6
% of budget funded	48	31
% available funding from domestic sources	3	5
% available funding from Global Fund	76	56

NTP Budget (blue) and available funding (green) (US\$ millions)



UNITED REPUBLIC OF TANZANIA

POPULATION 2010 (MILLIONS) **45**

ESTIMATES OF BURDEN 2010 ^a	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	5.8 (4.7–6.9)	13 (11–15)
Prevalence (incl HIV)	82 (39–130)	183 (87–281)
Incidence (incl HIV)	79 (75–85)	177 (166–189)
Incidence (HIV-positive)	30 (28–32)	67 (62–71)
Case detection, all forms (%)	77 (72–82)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	24 769 (42)	Relapse	1 430 (38)
Smear-negative	21 184 (36)	Treatment after failure	96 (3)
Smear unknown	0 (0)	Treatment after default	255 (7)
Extrapulmonary	13 715 (23)	Other	2 004 (53)
Other			
Total new	59 668	Total retreatment	3 785
Total < 15 years	5 216		

Total new and relapse	61 098	(96% of total)
Total cases notified	63 453	


DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	100
Paediatric formulations procured	Yes

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	88
New smear-negative/extrapulmonary	88
Retreatment	83

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	1.1 (0.30–2.8)
% of retreatment TB cases with MDR-TB	0.0 (0.0–5.9)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	510 (140–1 300)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	0 (0–220)

MDR-TB REPORTED CASES 2010

	New	Retreatment	Total
Cases tested for MDR-TB	201	246	474
% of notified tested for MDR-TB	<1	6	<1
Confirmed cases of MDR-TB	9	22	34
MDR-TB patients started treatment			17

LABORATORIES


	2009	2010	2011
Smear (per 100 000 population)	1.6	1.6	1.6
Culture (per 5 million population)	0.1	0.4	0.8
DST (per 5 million population)	0.1	0.2	0.3

Second-line DST available	In and outside country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	56 849
% of TB patients with known HIV status	90
TB patients that are HIV-positive	21 662
% of tested TB patients that are HIV-positive	38
% HIV-positive TB patients started on CPT	92
% HIV-positive TB patients started on ART	35
HIV-positive people screened for TB	321 436
HIV-positive people provided with IPT	


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	39	42
Available funding (US\$ millions)	19	19
% of budget funded	48	46
% available funding from domestic sources	36	38
% available funding from Global Fund	30	27

NTP Budget (blue) and available funding (green) (US\$ millions)



VIET NAM

POPULATION 2010 (MILLIONS) **88**

ESTIMATES OF BURDEN 2010 ^a	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	29 (19–43)	34 (21–49)
Prevalence (incl HIV)	290 (130–510)	334 (147–576)
Incidence (incl HIV)	180 (130–220)	199 (152–253)
Incidence (HIV-positive)	7.6 (4.6–11)	8.6 (5.2–13)
Case detection, all forms (%)	54 (43–71)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	52 145 (59)	Relapse	6 834 (81)
Smear-negative	18 237 (21)	Treatment after failure	595 (7)
Smear unknown	0 (0)	Treatment after default	385 (5)
Extrapulmonary	17 651 (20)	Other	594 (7)
Other	0 (0)		
Total new	88 033	Total retreatment	8 408
Total < 15 years	112		

Total new and relapse	94 867	(96% of total)
Total cases notified	99 022	


DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	100
Paediatric formulations procured	No

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	92
New smear-negative/extrapulmonary	92
Retreatment	73

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	2.7 (2.0–3.7)
% of retreatment TB cases with MDR-TB	19 (14–25)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	1 900 (1 400–2 600)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	1 600 (1 200–2 100)

MDR-TB REPORTED CASES 2010	New	Retreatment	Total
Cases tested for MDR-TB			
% of notified tested for MDR-TB			
Confirmed cases of MDR-TB			101
MDR-TB patients started treatment			101


LABORATORIES	2009	2010	2011
Smear (per 100 000 population)	0.9	0.9	0.9
Culture (per 5 million population)	1.3	1.3	1.4
DST (per 5 million population)	0.1	0.1	0.1

Second-line DST available	In country
National Reference Laboratory	Yes

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	42 356
% of TB patients with known HIV status	43
TB patients that are HIV-positive	3 515
% of tested TB patients that are HIV-positive	8
% HIV-positive TB patients started on CPT	62
% HIV-positive TB patients started on ART	43
HIV-positive people screened for TB	
HIV-positive people provided with IPT	1 317


CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	59	74
Available funding (US\$ millions)	18	15
% of budget funded	31	20
% available funding from domestic sources	26	31
% available funding from Global Fund	66	62

NTP Budget (blue) and available funding (green) (US\$ millions)



ZIMBABWE

POPULATION 2010 (MILLIONS) **13**

ESTIMATES OF BURDEN 2010 ^a	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	3.4 (2.1–5.1)	27 (17–40)
Prevalence (incl HIV)	51 (23–80)	402 (185–639)
Incidence (incl HIV)	80 (61–100)	633 (486–799)
Incidence (HIV-positive)	60 (47–76)	480 (371–603)
Case detection, all forms (%)	56 (44–72)	

CASE NOTIFICATIONS 2010

New cases	(%)	Retreatment cases	(%)
Smear-positive	11 654 (27)	Relapse	1 337 (29)
Smear-negative	18 341 (43)	Treatment after failure	135 (3)
Smear unknown	6 816 (16)	Treatment after default	157 (3)
Extrapulmonary	6 061 (14)	Other	3 056 (65)
Other	0 (0)		
Total new	42 872	Total retreatment	4 685
Total < 15 years	4 371		

Total new and relapse	44 209	(93% of total)
Total cases notified	47 557	


DRUG REGIMENS

Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	100
Paediatric formulations procured	Yes

TREATMENT SUCCESS RATE 2009 (%)

New smear-positive	78
New smear-negative/extrapulmonary	74
Retreatment	80

TREATMENT SUCCESS RATE (%)



MDR-TB, ESTIMATES AMONG NOTIFIED CASES^a

% of new TB cases with MDR-TB	1.9 (1.0–3.3)
% of retreatment TB cases with MDR-TB	8.3 (1.8–23)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	700 (370–1 200)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	390 (84–1 000)


MDR-TB REPORTED CASES 2010	New	Retreatment	Total
Cases tested for MDR-TB			26
% of notified tested for MDR-TB			<1
Confirmed cases of MDR-TB			17
MDR-TB patients started treatment			27

LABORATORIES	2009	2010	2011
Smear (per 100 000 population)	1.0	0.9	1.4
Culture (per 5 million population)	0.4	0.8	0.8
DST (per 5 million population)	0.4	0.8	0.8
Second-line DST available	No		
National Reference Laboratory	Yes		

^a Ranges represent uncertainty intervals.


INCIDENCE (HIV+TB red), notifications (black)

(rates per 100 000 population)




PREVALENCE

(rate per 100 000 population)



MORTALITY EXCLUDING HIV


(rate per 100 000 population)



TB/HIV 2010

TB patients with known HIV status	38 012
% of TB patients with known HIV status	80
TB patients that are HIV-positive	28 662
% of tested TB patients that are HIV-positive	75
% HIV-positive TB patients started on CPT	18
% HIV-positive TB patients started on ART	30
HIV-positive people screened for TB	
HIV-positive people provided with IPT	

CPT (pink) and ART (brown) for HIV-positive TB patients (blue)



FINANCING

	2011	2012
Total budget (US\$ millions)	26	
Available funding (US\$ millions)	6	
% of budget funded	24	
% available funding from domestic sources	5	
% available funding from Global Fund	79	

NTP Budget (blue) and available funding (green) (US\$ millions)

